Same Indication

Ipilimumab vs Osimertinib Mesylate

Ipilimumab vs Osimertinib Mesylate: Overview

This comparison examines the pharmacological differences between Ipilimumab and Osimertinib Mesylate.

Mechanism of Action

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Pharmacokinetics

Half-life: Ipilimumab β€” 14.7 days.

Chemical Properties

Type: Ipilimumab β€” Antibody; Osimertinib Mesylate β€” Small molecule.